Peru bill proposes to eliminate tax for COVID-19 health products

A draft law submitted last week to Peru’s unicameral Congress proposes to exempt active pharmaceutical ingredients (APIs), drugs, medical equipment and materials for the treatment and prevention of COVID-19 from value added tax (IGV). If approved, the measure would extend 6 months after the conclusion of the health emergency.

The bill is aimed at reducing final prices for patients, which could potentially drive up sales. It is similar to a measure excluding cancer treatments from IGV that was adopted in 2001 to improve medicine access.

According to proponent Erwin Tito Ortega, COVID-19-related medicines have experienced steep price increases during the epidemic, which has affected access by patients.


Related news
Chinese biotech Clover Biopharmaceuticals Inc., has received USD 66 million from the Coalition for Epidemic Preparedness Innovations (CEPI) in support of the firm’s COVID-19 vaccine development efforts.
A report from Switzerland-based insurance firm Swiss Re Institute reveals that China’s online health insurance market is expected to expand at a compound average growth rate (CAGR) of 43% each year till 2025.
Venezuelan vice President Delci Rodríguez this week announced that the Rafael Rangel National Sanitation Institute (INHRR) has included Cuban state company BioCubaFarma’s Jusvinza (immunomodulating synthetic peptide 814) and Nasalferón (nasally administered interferon) into the COVID-19 treatment protocol.
Argentina's Universidad Nacional del Litoral (UNL) has announced that it received funding from the Ministry of Science, Technology and Productive Innovation (MINCYT) to create SARS-CoV-2 diagnosis kits and virus-like particle (VLP) vaccine candidates from recombinant viral proteins.
A research team at Ecuador’s UTE University last week announced that they identified dozens of drugs that can potentially be repurposed against COVID-19.
Recent news
According to GBI analysis, Colombia’s National Food and Drug Surveillance Institute (INVIMA) recently approved Pfizer subsidiary Wyeth’s antihemorrhagic BeneFIX (recombinant coagulation factor IX), Pfizer’s human growth hormone analog Somavert (pegvisomant), and Mundipharma’s antineoplastic Difolta (pralatrexate).
Argentina’s Ministry of Health (MoH) this week launched two drug procurement processes.
Mexico’s Congress last week passed an Industrial Innovation Protection Law, which was announced last month.
Paraguay's Ministry of Health (MSPBS) this week launched its Drugs and Medical Supplies National Monitoring System, an online platform that keeps track of health products distribution in the public healthcare system as well as their cost.
Germany-based giant Merck KGaA has opened its M Lab Collaboration Center in Pudong, at the heart of the biomedical sciences and research community in Shanghai.
The cloud summit of World Artificial Intelligence Conference (WAIC) held in Shanghai this year saw China’s technology giant Tencent launch iDrug, its first AI-empowered drug research and development (R&D) platform, designed to galvanize novel drug development via technology. iDrug covers the whole process of pre-clinical development: protein structure screening, virtual screening, molecular design and optimization, and synthetic route planning.
China-based Suzhou Zelgen Biopharmaceuticals Co., Ltd (688266.SH) announced the go-ahead from the National Medical Products Administration (NMPA) to initiate a clinical study for its donafenib combined with Genor Biopharma Co., Ltd’s programmed death-1 (PD-1) inhibitor genolimzumab in advanced hepatocellular carcinoma (HCC), gastric cancer including gastroesophageal junction adenocarcinoma (GC/GEJ), renal cell carcinoma (RCC), colorectal cancer (CRC), and other advanced solid tumors. Donafenib (CM4307) is a small-molecule oral multi-kinase inhibitor with activity against serine-threonine kinase (Raf/MEK/ERK) signaling, vascular endothelial growth factor receptor (VEGFRs) and platelet-derived growth factor receptor (PDGFR), designed to directly and indirectly inhibit tumor cell proliferation and growth.
Analytics Snapshot

Analytics Snapshot